Therapy of Secondary Acute Nonlymphocytic Leukemia with Cytarabine

Therapy of secondary leukemia

“…Recommendations for therapy have often been intuitive and based on information from select phase II data. 8 Additionally, there remains a reluctance among many practicing physicians to enter such patients on clinical trials. There have been no phase III studies of induction or post-remission therapy of secondary leukemias and no evidence is available to suggest that any regimen is better than standard AML induction therapy consisting of an anthracycline and cytarabine (3 + 7), or similar.…”

How I treat acute myeloid leukemia

“…70 Historically, it was presumed that every patient with therapyrelated leukemia had an adverse prognosis and that standard induction therapy was inappropriate; high-dose cytarabine was suggested in one report. 71 However, there is no evidence that any induction therapy is superior to the standard 3 ϩ 7 regimen. Among young adults, quite remarkably, prospective studies report an almost identical CR rate of 55% to 60% for patients treated with recognized unfavorable cytogenetics, and there are no reports that anything is better than this (Table 2).…”

Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia

“…1,2 The prognosis of refractory leukemia is poor. [3][4][5][6][7][8][9][10] In an attempt to overcome this feature, salvage therapy tends to be more intensive than standard induction therapy using, when possible, higher dose or other non cross-resistant drugs not previously delivered. These kind of treatments are also used as first-line therapy in other high risk leukemia, such as in the setting of secondary AML (s-AML).…”